3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Observational
2
Sponsor
Cancer Type
Tumor-Agnostic
6
Gastrointestinal
4
Thoracic
2
Other hematologic neoplasm
2
NET
2
Lymphoid
2
Genitourinary
2
Endocrine
2
Sarcoma
1
Other solid neoplasm
1
Head & Neck
1
Gynecologic
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Wilms Tumor
1
Prostatic Neoplasms
1
Interventions
pembrolizumab
183
Magnetic Resonance Spectroscopy
164
Specimen Handling
135
enzalutamide
124
Nivolumab
123
Gemcitabine
99
Docetaxel
96
Radiosurgery
92
Prednisone
84
Abiraterone Acetate
82
Androgen Antagonists
81
Radiotherapy
74
apalutamide
68
Cisplatin
65
Ipilimumab
64
darolutamide
61
Biopsy
60
Carboplatin
57
abiraterone
56
cabozantinib
54
Leuprolide
53
enfortumab vedotin
49
Radiation
47
Standard of Care
44
Pluvicto
43
atezolizumab
38
Surveys and Questionnaires
38
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
37
X-Rays
37
olaparib
35
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Data Collection
×
Genitourinary
×
1 year
×
Clear all
NCT04423484
2026-03-02
GFANEPHRO20
French Africa Pediatric Oncology Group
Recruiting
1,000 enrolled
NCT03516110
2026-01-23
PRISME
Ipsen
Completed
831 enrolled